ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 22159
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 22159

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

 

Disease Types: Breast Cancer Research

Available at:

Virginia Oncology Associates